secwatch.observer — SEC 8-K summary
======================================

Issuer:     FRACTYL HEALTH, INC. (GUTS)
CIK:        0001572616
Form:       8-K
Filed at:   2026-08-10T20:05:17+00:00
Accession:  0001193125-26-342343
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fractyl Q2 net loss $25.5M; REMAIN-1 data show 84% weight-loss maintenance
--------------------------------------------------------------------------

- Net loss $25.5M vs $27.9M YoY; R&D down to $13.8M from $21.2M.
- Cash $47.1M at 6/30/26; runway into early 2027, beyond pivotal readout.
- REMAIN-1 Midpoint: Revita patients maintained 84% of weight loss vs 46% sham (optimized subgroup).
- REVEAL-1: ~78% weight-loss maintenance after single Revita; no serious device-related AEs.
- Pivotal topline due early Q4 2026; potential FDA De Novo submission late Q4 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1572616/000119312526342343/0001193125-26-342343-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1572616/000119312526342343/guts-20260810.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-342343

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer